AB Science provides clarification regarding the article published yesterday in the newspaper Les Echos related to the investi...
22 Novembre 2019 - 8:16AM
Paris, November 22, 2019, 8.15am
Clarification regarding the article
published yesterday in the newspaper Les Echos related to the
investigation by the French market authorities
AB Science SA (Euronext -
FR0010557264 - AB) has taken note of the article published
yesterday in the newspaper Les Echos regarding an investigation led
by the Financial Markets Authority (Autorité des Marchés Financiers
or AMF) related to AB Science financial information and market
trading.
AB Science reminds that this investigation which
started in 2017 was disclosed when the Company released its annual
financial report for the fiscal year ended December 31, 2018.
AB Science is puzzled to read in the press an
inaccurate and unfounded statement of the AMF investigators, in
violation of the rights of the Company and its management, despite
the fact that the investigation is still ongoing and that no formal
grievances have been notified.
AB Science, which does not intend to comment on
an ongoing investigation, reminds that the facts outlined in this
article are formally contested and that the management of the
Company is totally confident about the outcome of this
investigation.
About AB ScienceFounded in
2001, AB Science is a pharmaceutical company specializing in the
research, development and commercialization of protein kinase
inhibitors (PKIs), a class of targeted proteins whose action are
key in signaling pathways within cells. Our programs target only
diseases with high unmet medical needs, often lethal with short
term survival or rare or refractory to previous line of
treatment.
AB Science has developed a proprietary portfolio
of molecules and the Company’s lead compound, masitinib, has
already been registered for veterinary medicine and is developed in
human medicine in oncology, neurological diseases, and inflammatory
diseases. The company is headquartered in Paris, France, and listed
on Euronext Paris (ticker: AB).
Further information is available on AB Science’s website:
www.ab-science.com.
Forward-looking Statements - AB ScienceThis
press release contains forward-looking statements. These statements
are not historical facts. These statements include projections and
estimates as well as the assumptions on which they are based,
statements based on projects, objectives, intentions and
expectations regarding financial results, events, operations,
future services, product development and their potential or future
performance.
These forward-looking statements can often be
identified by the words "expect", "anticipate", "believe",
"intend", "estimate" or "plan" as well as other similar terms.
While AB Science believes these forward-looking statements are
reasonable, investors are cautioned that these forward-looking
statements are subject to numerous risks and uncertainties that are
difficult to predict and generally beyond the control of AB Science
and which may imply that results and actual events significantly
differ from those expressed, induced or anticipated in the
forward-looking information and statements. These risks and
uncertainties include the uncertainties related to product
development of the Company which may not be successful or to the
marketing authorizations granted by competent authorities or, more
generally, any factors that may affect marketing capacity of the
products developed by AB Science, as well as those developed or
identified in the public documents filed by AB Science with the
Autorité des Marchés Financiers (AMF), including those listed in
the Chapter 4 "Risk Factors" of AB Science reference document filed
with the AMF on November 22, 2016, under the number R. 16-078. AB
Science disclaims any obligation or undertaking to update the
forward-looking information and statements, subject to the
applicable regulations, in particular articles 223-1 et seq. of the
AMF General Regulations.
For additional information, please contact:
AB ScienceFinancial
Communication & Media Relations investors@ab-science.com
Ab Science (EU:AB)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Ab Science (EU:AB)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024